OTCMKTS:AZNCF

AstraZeneca (AZNCF) Stock Forecast, Price & News

$137.93

+3.98 (+2.97%)

(As of 09/22/2023 ET)

Compare

Today's Range: $137.93
▼
$137.93
50-Day Range: $130.08
▼
$147.00
52-Week Range: $104.50
▼
$153.10

Volume: 731 shs
Average Volume: 3,089 shs
Market Capitalization: N/A

P/E Ratio: 169.03
Dividend Yield: 2.03%
Price Target: $13,500.00

AstraZeneca MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 9,687.6% Upside
$13,500.00 Price Target
Short Interest: Bearish
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.09
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
AstraZeneca has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13,500.00, AstraZeneca has a forecasted upside of 9,687.6% from its current price of $137.93.
Amount of Analyst Coverage
AstraZeneca has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
Short Interest Ratio / Days to Cover
AstraZeneca has a short interest ratio ("days to cover") of 22.8, which indicates bearish sentiment.
Change versus previous month
Short interest in AstraZeneca has recently increased by 10.70%, indicating that investor sentiment is decreasing significantly.

1.7

Dividend Strength

Dividend Leadership
AstraZeneca is a leading dividend payer. It pays a dividend yield of 3.89%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
AstraZeneca does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of AstraZeneca is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AZNCF.

2.3

News and Social Media Coverage

News Sentiment
AstraZeneca has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for AstraZeneca this week, compared to 7 articles on an average week.
Search Interest
1 people have searched for AZNCF on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AstraZeneca insiders have not sold or bought any company stock.
Percentage Held by Institutions
40.87% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of AstraZeneca is 169.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 115.37.
Price to Earnings Ratio vs. Sector
The P/E ratio of AstraZeneca is 169.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 95.58.

See Top Rated MarketRank™ Stocks Here

About AstraZeneca (OTCMKTS:AZNCF) Stock

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZNCF Price History

30 days | 90 days | 365 days | Advanced Chart

AZNCF Stock News Headlines

August 23, 2023 | marketbeat.com

20 Best Healthcare Dividend Stocks to Invest in (AZNCF)

Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.

September 22, 2023 | thetimes.co.uk

Breast cancer drug trial boosts AstraZeneca

September 23, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 22, 2023 | financialpost.com

Former director sues AstraZeneca after bonus cut for working at home

September 22, 2023 | msn.com

AstraZeneca shares jump after positive breast cancer drug trial results

September 22, 2023 | bloomberg.com

AstraZeneca, Daiichi Breast Cancer Drug Shows Benefits

September 21, 2023 | msn.com

AstraZeneca Sued by Staffer Whose Bonus Was Cut for Working at Home

September 20, 2023 | wsj.com

AstraZeneca’s Rare-Disease Unit Buy Pfizer Portfolio for $1 Bln

September 23, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

September 20, 2023 | marketwatch.com

AstraZeneca's Rare-Disease Unit Buys Pfizer Portfolio for $1 Bln

September 19, 2023 | msn.com

AstraZeneca unveils new sustainable offices at Dubai Science Park

September 18, 2023 | msn.com

AstraZeneca unveils new sustainable offices at TECOM Group’s Dubai Science Park

September 18, 2023 | americanbankingnews.com

Short Interest in AstraZeneca PLC (OTCMKTS:AZNCF) Expands By 10.7%

September 15, 2023 | uk.news.yahoo.com

EU recommends approval of AstraZeneca and Daiichi's drug for a type of lung cancer

September 15, 2023 | marketwatch.com

AstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EU

September 15, 2023 | msn.com

AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths

September 14, 2023 | finance.yahoo.com

AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment

September 11, 2023 | msn.com

AstraZeneca seeks to calm CEO speculation after shares drop

September 11, 2023 | marketwatch.com

AstraZeneca Says Datopotamab Deruxtecan Combined With Imfinzi Shows High Disease Control Rates

September 11, 2023 | bloomberg.com

AstraZeneca Lung Cancer Drug Works Better With Chemotherapy

September 9, 2023 | msn.com

AstraZeneca boss Sir Pascal Soriot looks to step down

September 8, 2023 | finance.yahoo.com

AstraZeneca PLC: AstraZeneca: Late-Stage Pipeline Looks Increasingly Well Positioned to Support Long-Term Growth

September 6, 2023 | msn.com

AstraZeneca mulls risk strategy for Ultomiris following FDA response letter

September 6, 2023 | msn.com

AstraZeneca hopes to make clinical trial operations carbon-negative by 2030

September 6, 2023 | marketwatch.com

AstraZeneca PLC ADR falls Wednesday, still outperforms market

September 6, 2023 | marketwatch.com

AstraZeneca Says FDA Has Requested Improvements to Ultomiris's Risk Evaluation

September 5, 2023 | msn.com

Chinese NMPA approves AstraZeneca’s Calquence for leukaemia

See More Headlines

Receive AZNCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZNCF Company Calendar

Ex-Dividend for 9/11 Dividend: 8/09/2023
Dividend Payable: 9/11/2023
Today: 9/23/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Drug Manufacturers—General
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:AZNCF
CUSIP: N/A
CIK: 901832
Web: www.astrazeneca.com
Phone: 442037495000
Fax: N/A
Employees: 83,500
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13,500.00
High Stock Price Forecast: $13,500.00
Low Stock Price Forecast: $13,500.00
Forecasted Upside/Downside: +9,687.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 169.03
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Pascal Soriot D.V.M. (Age 64)
M.B.A., CEO & Exec. Director
Comp: $5.92M

Dr. Aradhana Sarin M.D. (Age 48)
Exec. Director
Comp: $3.39M

Ms. Pam P. Cheng (Age 52)
EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board

Mr. Andrew P. Barnett
Head of Investor Relations

Mr. Jeffrey Pott
CHRO, Chief Compliance Officer, Gen. Counsel & Member of External Sustainability Advisory Board

Gonzalo Vina
Head of Global Media Relations

Dr. Menelas Pangalos Ph.D. (Age 56)
EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board

Dr. Ruud Dobber Ph.D.
Exec. Vice-Pres of BioPharmaceuticals Bus. Unit

Dr. Susan Mary Galbraith M.D. (Age 57)
Ph.D., Exec. VP of Oncology R&D

Mr. Leon Wang
Exec. VP of International & China Pres

Key Competitors

View All Competitors

Institutional Ownership

Boston Common Asset Management LLC
Bought 41,935 shares on 7/24/2023
Ownership: 0.000%

View All Institutional Transactions

AZNCF Stock - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AZNCF shares.
View AZNCF analyst ratings or view top-rated stocks.
What is AstraZeneca's stock price forecast for 2023?: 1 analysts have issued 12 month target prices for AstraZeneca's stock. Their AZNCF share price forecasts range from $13,500.00 to $13,500.00. On average, they expect the company's share price to reach $13,500.00 in the next twelve months. This suggests a possible upside of 9,687.6% from the stock's current price.
View analysts price targets for AZNCF or view top-rated stocks among Wall Street analysts.
How have AZNCF shares performed in 2023?: AstraZeneca's stock was trading at $139.28 at the beginning of the year. Since then, AZNCF shares have decreased by 1.0% and is now trading at $137.93.
View the best growth stocks for 2023 here.
Are investors shorting AstraZeneca?: AstraZeneca saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 99,300 shares, an increase of 10.7% from the August 15th total of 89,700 shares. Based on an average daily volume of 4,400 shares, the days-to-cover ratio is currently 22.6 days.
View AstraZeneca's Short Interest.
How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?: AstraZeneca announced a dividend on Saturday, July 29th. Investors of record on Friday, August 11th will be paid a dividend of $0.93 per share on Monday, September 11th. The ex-dividend date of this dividend is Wednesday, August 9th.
Read our dividend analysis for AZNCF.
Is AstraZeneca a good dividend stock?: AstraZeneca (OTCMKTS:AZNCF) pays an annual dividend of $2.80 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for AZNCF.

What is AstraZeneca's stock symbol?: AstraZeneca trades on the OTCMKTS under the ticker symbol "AZNCF."
Who are AstraZeneca's major shareholders?: AstraZeneca's stock is owned by a number of retail and institutional investors. Top institutional investors include Boston Common Asset Management LLC (0.00%).
How do I buy shares of AstraZeneca?: Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AstraZeneca's stock price today?: One share of AZNCF stock can currently be purchased for approximately $137.93.
How many employees does AstraZeneca have?: The company employs 83,500 workers across the globe.
How can I contact AstraZeneca?: AstraZeneca's mailing address is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom. The official website for the company is www.astrazeneca.com. The company can be reached via phone at 442037495000.

This page (OTCMKTS:AZNCF) was last updated on 9/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial